Computable Features Required to Evaluate the Efficacy of Drugs and a Universal Algorithm to Find Optimally Effective Drug in a Drug Complex by Wang, Kui et al.
Computable Features Required to Evaluate the Efficacy
of Drugs and a Universal Algorithm to Find Optimally
Effective Drug in a Drug Complex
Kui Wang
1, Wei Cui
1, Gang Hu
1, Jianzhao Gao
1, Zhonghua Wu
1, Xingye Qiu
1, Jishou Ruan
1,3*, Yi Feng
2,
Zhi Qi
2, Yiming Shao
2, Jack A. Tuszynski
4,5
1College of Mathematical Sciences and LPMC, Nankai University, Tianjin, People’s Republic of China, 2National Center for AIDS/STD Control and Prevention, Chinese
Center for Disease Control and Prevention, Beijing, People’s Republic of China, 3National Key Laboratory for Pharmaceutical chemistry and biology at Nankai University,
Tianjin, People’s Republic of China, 4Department of Physics, University of Alberta, Edmonton, Alberta, Canada, 5Department of Oncology, University of Alberta,
Edmonton, Alberta, Canada
Abstract
Background: The H1N1 pandemic in 2009 and the H5N1 pandemic in 2005 demonstrated that the drugs approved to treat
influenza A viruses have low efficacy. This provided a stimulus for new studies of influenza A viruses in the context of the
methods used in drug design developed over the past 100 years. Finding new universal drugs is the ultimate goal but its
long time horizon is incompatible with emergency situations created by reoccurring influenza outbreaks. Therefore, we
propose a computer-aided method for finding efficacious drugs and drug complexes based on the use of the DrugBank
database.
Methods: (1) We start by assembling a panel of target proteins. (2) We then assemble a panel of drugs. (3) This is followed
by a selection of benchmark binding pockets based on the panel of target proteins and the panel of drugs. (4) We generate
a set of computational features, which measure the efficacy of a drug. (5) We propose a universal program to search for
drugs and drug complexes. (6) A case study we report here illustrates how to use this universal program for finding an
optimal drug and a drug complex for a given target. (7) Validation of the Azirchromycin and Aspirin complex is provided
mathematically. (8) Finally, we propose a simple strategy to validate our computational prediction that the Azirchromycin
and Aspirin complex should prove clinically effective.
Result: A set of computable features are mined and then based on these features, a universal program for finding the
potential drug &drug complexes is proposed. Using this universal program, the Azirchromycin and Aspirin complex is
selected and its efficacy is predicted mathematically. For clinical validation of this finding, future work is still required.
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Introduction
1 General background
The H5N1 pandemic in 2005 and the H1N1pandemic in 2009
demonstrated the fact that there are no effective drugs to
specifically treat infections caused by the Influenza A virus.
Consequently, there is renewed interest in the studies of influenza
A viruses. The recent discovery of CR6261 published by Throsby
et al ([1], PLoS 2008), the spatial structure of HA binding with
CR6261 (3gbn) published by Ekiert et al ([2], Science 2009) and
the family of CR6261-like antibodies published by Sui et al ([3],
Nat. Str. & Mol. Bio. 2009) provided a solid basis for future work
on new vaccines. The first novel insight is the concept of universal
vaccines proposed by Nabel et al ([4], Nature Medicine 2010) and
Wei et al ([5], Science 2010). Following the prophylactic and
therapeutic tests of the efficacy of CR6261 by Friesen et al ([6],
PLoS 2010), they subsequently offered an insight suggesting to use
CR6261 in combination with drug such as oseltamivir or
zanamivir in order to effectively protect against all seasonal
influenza viruses. These two recent insights provide a conceptual
basis for new studies of influenza A viruses.
Inspired by the second insight, we propose to find a new drug
with drug complexes, which would respond to emergency
situations by repurposing old drugs rather than designing new
ones from scratch. For simplicity, henceforth we will use the term
‘‘drug & drug’’ to represent ‘‘a combination of a drug with another
drug’’. In order to be able to accomplish this we need to determine
the following: (1) what drugs are presently approved to treat
influenza A viruses? (2) What proteins are the potential targets of
these drugs? (3) What pockets are the binding sites for these drugs?
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33709(4) What factors were ignored when these approved drugs were
designed?
The outline of this paper is as follows:
(1) First, we assemble a panel of target proteins. It contains all
potential proteins having either complete or partial 3D
structures. While each drug has an assumed target protein
(referred to as the benchmark protein), it is not always
guaranteed that this is the actual benchmark protein. Using a
panel of target proteins, we may be able to verify if a given
protein is the benchmark protein for a given drug.
(2) We then assemble a panel of drugs. To confirm that a drug is
effective in treating influenza A, we should compare it with
other effective drugs and other non-influenza viral drugs.
Therefore, we assemble the known influenza viral drugs and
the known non-influenza viral drugs to form a panel of drugs.
Of course, we also ensure the uniformity of the sizes of the
drug molecules when selecting the non-influenza viral drugs.
(3) We next assemble a panel of benchmark pockets based on the
panel of target proteins and the panel of drugs. At this point it
is still unclear where on a protein surface the binding site is
located (referred to as the benchmark pocket) for a given drug
even if we know that the given protein is the benchmark
protein for the drug. Therefore, determining the set of
benchmark pockets is the only way to validate the efficacy of a
drug or to design a new drug. We call this set the panel of
benchmark pockets.
(4) We then propose a set of computable features required to
measure the efficacy of a drug. Each benchmark pocket has a
specific spatial extent and performs a specific function. A drug
(either already designed or yet to be designed) is just a ligand
molecule that needs to fit into the spatial extent created by the
pocket and to bind strongly enough to the target. Therefore,
we should individually find computable features of each
benchmark pocket as accurately as possible so that we can
predict whether or not an approved drug (or a drug yet to be
designed) satisfies these features.
(5) Finally, we propose a universal program to find the potential
drug & drug complexes. This is a very time-consuming
process, which requires high performance computing resourc-
es.
(6) We conclude by providing a case study that demonstrates that
drug & drug complex (Azithromycin & Aspirin) can be found
using this universal program. This drug & drug complex is
predicted to be effective through mathematical analysis and
computational algorithms.
(7) We propose a simple and operable strategy to validate these
predictions clinically.
2 What tools are used?
The first tool used in this paper is AutoDock software. The
kernel index of AutoDock is the minimal free energy (MFE) which
measures the fitness of a drug binding to a pocket. This involves
geometrical features, chemical features and physical features [7–
11]. The second tool is the Ligand Explorer which is an associated
software package provided by DrugBank or Protein Data Bank
(PDB). Using Ligand Explorer, we can fully understand the
interactions between a drug and a binding pocket including the
number of the non-covalent bonds and the distribution of the non-
covalent bonds in the drug binding pocket. The third tool is
molecular dynamics (MD) simulation software. MD simulation is
regarded as a computational bridge between theory and
experiment and between microscopic and macroscopic analyses.
We refer the reader to relevant literature on the subject [12].
Materials and Methods
1 The panel of target proteins
To design drugs or to evaluate the efficacy of an approved drug,
we need to know either its complete 3D structure or at least a
partially-determined spatial structure (e.g. a functional domain) of
the target protein. Among all 11 influenza A viral proteins, only
hemagglutinin (HA) and neuraminidase (NA) currently have
complete 3D structures (i.e., 1rd8 and 2hu4). The partial
structures (1nyj) of M2 have been known for a long time but a
complete structure is still unknown. Partial spatial structures of
trimeric polymerases (PA, PB1 and PB2) (i.e., 3hw3, 3hw4, 3hw5,
3hw6, 3cm8 and 2znl) have been published but their complete
structures are still unknown. Therefore, the selection of target
proteins to be used to design drugs is limited. Below we briefly
describe these complete or partial 3D structures:
1. 1rd8 is the crystal structure of the uncleaved human H1
hemagglutinin from the extinct 1918 influenza virus published
by Stevens et al in 2004 [13]. Of course, many versions of a
complete spatial structure of HA observed in different subtypes
(i.e., human H3, avian H5 and avian H7) have been submitted
to the PDB database since HA is a unique target protein for the
development of vaccines.
2. 2hu4 is a complete spatial structure of neuraminidase (NA)
derived from the H5N1 avian influenza neuraminidase [14],
but all subtypes in group N1 share the same complete spatial
structure. The function of this protein is to release the N-
acetylneuraminic acid in order to cleave HA so that viruses can
escape from infected cells. Using NA as the target protein, two
drugs Oseltamivir and Zanamivir were designed.
3. 1nyj is the spatial structure of the well-known M2-TMD
(transmembrane tetrameric bundle) published by Nishimura et
al in 2002 [15]. It represents an ion channel of a viral particle
and therefore it is a traditional benchmark pocket. Targeting
1njy, the drug Amantadine was designed to prevent the germ
cytoplasm inside the viral lipid envelope from jetting into the
host cell to be replicated.
4. 3cm8 is the partial structure of the PA_C and PB1_N complex
published by He et al ([16], Nature 2008). In the same volume
of Nature in 2008, Obayashi et al [17] also published this
partial structure named 2znl. Following from [16] we may find
more details regarding the topological diagram of PA_C and
the 3_10 helix formed by PB1_N, which is called eta2 and it
corresponds to the 3_10 helix called eta1 on PA_C. The
molecular basis for the interaction between the jaws and the
tongue has been discussed in detail [18]. However, the
interaction between eta1 and eta2 has not been elucidated.
5. 3hw3, 3hw4, 3hw5 and 3hw6 are four versions of the spatial
structure of PA_N in complex with UMP, TMP, AMP and
Mn, respectively, published jointly by Rao’s and Liu’s groups
in 2009 [19]. These four versions become the same if we
eliminate the substrates UMP, TMP, AMP and Mn. Therefore
we select 3hw3 as the representative of the asymmetric unit.
For 3hw3, we will find four identical chains (A, B, C and D)
and each identical chain is just PA_N (1–196). These four
chains form an asymmetric unit.
In summary, the information about the spatial structures of the
influenza A viral proteins, is still very incomplete. Our panel of
potential target proteins used to design drugs or vaccines only
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3hw3.
2 The panel of drugs
In the past, Amantadine, Zanamivir and Oseltamivir were
approved for the treatment of influenza A viruses. Nevertheless,
the efficacies of these drugs insufficient to ensure that these drugs
may cure either H1N1 or H5N1 infected patients. A popular
explanation of this situation is that influenza A viruses mutate fast
enough to develop drug resistance. This is equivalent to saying that
influenza viruses have the intelligence that allows them to change
themselves fast enough to make the drugs ineffective. We do not
subscribe to this point of view since the mechanism of drug action
of Amantadine is known and it involves the benchmark pocket,
which is highly conserved in all subtypes. Furthermore, for
Zanamivir and Oseltamivir, we can also find their benchmark
pocket, which is highly conserved in all subtypes within group N1.
Therefore, we should first analyze whether or not there is a hidden
design flaw involving Amantadine, Zanamivir and Oseltamivir
making these drugs ineffective. If a drug turns out to have no
design flaw, then we can look for other causes of drug resistance.
For this purpose, we need to construct a panel of drugs, which
includes both influenza anti-virals and non-influenza anti-virals. In
this paper we have selected nine drugs (i.e., Oseltamivir,
Zanamivir, Amantadine, Aspirin, Azithromycin, Isosorbide,
Vancomycin, Heroin and HEM) to form the panel of drugs
under study. Oseltamivir, Zanamivir and Amantadine have been
selected as influenza anti-virals (Friesen et al [6], Russell et al [13],
Nishimura et al [15] and Wang et al [20]). The six non influenza
viral drugs have been selected for comparison seems to be
arbitrary. It is a longer story to get the panel. The details is shown
in section 1 of Supporting Information S1, and we only show the
weights, the target proteins and the groups of these drugs in
Table 1 to tell readers this panel is balance and that 6 added drugs
are really non influenza viral drugs in the sense of biomedical. In
other word, the weights of three non influenza viral drugs
approximate to that of three influenza viral drugs, while the
weights of the other three non influenza viral drugs are strict
larger.
3 The panel of benchmark pockets
A drug’s efficacy is contingent on its binding to a pocket of the
target protein. Thus, for each drug we need to know the location
of its benchmark pockets. Consequently, we need to know the 3D
structure of the target protein and also a method is needed to
explore the exact location of a pocket. AutoDock is a readily
available and widely used software tool. On one occasion, we
suspected either we had misused the AutoDock or AutoDcok has
some major flaw because different drugs may be predicted to dock
with the same place.
We first exclude that we had operated AutoDock wrongly
because we had validated that Oseltamivir and Zanamivir can find
their benchmark pocket on their target protein NA, that
Amantadine can also find its benchmark pocket on its target
protein M2, and that Fosamprenavir, Indinavir, Nelfinavir,
Darunavir, Tipranavir and Amprenavir can also find their
benchmark pocket on their target protein HIV-1 protease.
We also exclude that AutoDock has major flaw after we
validated this result on a large panel of proteins and a large panel
of ligands. In fact, selecting 1rd8, 2hu4, 1nyj, 3cm8, 3hw3, 1g6l,
2jle, 2gv9, 3gbn, 3gbm, 3fku, 3sdy, 3ztn and 3ztj as the target
proteins, and choosing Amantadine, Aspirin, Azithromycin,
HEM, Heroin, Isosorbide, Oseltamivir, Zanamivir and Vanco-
mycin as the panel of drugs, then all of these ligands are predicted
to be docked with the same pocket on each of above target
proteins if these ligands can be packed into this pocket, while all of
those ligands will arrive at the minimal value of minimal free
energy at a neighborhood of the pocket if those ligands can not be
packed into this pocket. Moreover, when the panel of ligands is
enlarged to 34 ligands, these 34 drugs are also predicted to be
docked with the same pocket uniformly. Furthermore, for the
proteins formed by subunits (i.e, 3hw3, 3gbn, 3gbm, 3fku, 3sdy,
3ztn and 3ztj), if we just use a subunit as the target protein, then all
ligands also are predicted to be docked with the same pocket on
the subunit. Of course, this pocket on a subunit is not same as that
pocket on entire protein. Especially, for the complete 3D-
structures obtained from subtypes of human H3, avian H5 and
avian H7, we repeat the same operations as for 1rd8, and find the
same pocket in the similar location. For more detail, please see
section 2 of Supporting Information S1.
After above validation, not only we confidently trust that
AutoDock is a reliable tool to find the benchmark pocket of drugs
on the given target protein, but also we believe that AutoDock
must contain a good preprocessing subprogram so that AutoDock
always may escape from the trap of the locally minimal value so
that all drugs may be sent to the same place to arrive at the global
minimal value of MFE. Encouraged by this advantage, we have
the idea to utilize this advantage sufficiently. In fact, if we input the
3D coordinates of a drug and the 3D coordinates of a protein, then
AutoDock will outputs a value of the minimal free energy (MFE)
and a predicted coordinates of the drug. Also, if we input a panel
of drugs with the 3D coordinates and the 3D coordinates of a
protein, then AutoDock will output a series of values of MFE and
the predicted coordinates of the drugs. Therefore, if we show out
all of these drugs with negative MFE using PyMOL according to
the predicted coordinates at same time, then these drugs will be
clustered in a void or a groove. And then we say this void/groove
on a given target protein is a benchmark pocket of these drugs. In
this way, we may know both the size and the location of the
benchmark pocket. For example, we denote these five benchmark
pockets on the target proteins 1rd8, 2hu4, 1nyj, 3cm8 and 3hw3 as
pocket_1rd8, pocket_2hu4, pocket_1nyj, pocket_3cm8 and pock-
et_3hw3, respectively. We use orally-administered drugs for these
benchmark pockets to show their binding locations (see
Figure 1(A)–(E)).
Nevertheless, AutoDock still has a minor flaw. In practice, the
predicted docking fashion may not be perfectly same as the real
fashion observed using x-ray. For example, the complex structure
of Indinavir docking with 2 bp6(one subtype of HVI-1 protease)
Table 1. The weight and the target protein of the drugs in
the panel.
drug weight Target protein groups
Vancomycin 1449.254 1pnv approved
Azithromycin 748.9845 50S ribosomal protein L4 approved
HEM 618.46 1bep experimental
Heroin 369.411 Mu-type opioid receptor illicit, experimental
Zanamivir 332.3098 NA (Neuraminidase) approved
Ossltamivir 312.4045 NA (Neuraminidase) approved
Isosorbide 191.1388 enzyme guanylate cyclase approved
Aspirin 180.1574 COX-1/COX-2 approved
Amantadine 151.2487 Proton channel protein M2 approved
doi:10.1371/journal.pone.0033709.t001
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structure of Indinavir docking with 2 bp6 predicted using
Autodock, through both they are packed into the same benchmark
pocket. Consequently, we should keep in mind that predicted
efficacy of a dug may not be perfectly same as the real case. It is
just a referential answer.
In the closing of this section, we state some information about
the panel of benchmark pockets.
1. pocket_1rd8 is the smallest and its function is unclear. We may
infer that it has no important function because the position of
pocket_1rd8 is not close to the epitope on the spike to be
docked by antibodies. Therefore, we ignore it.
2. pocket_2hu4 is mid-size and it represents the channel to release
the N-acetylneuraminic acid (C11H19NO9). Importantly, it is
highly conserved for these subtypes in group N1 and therefore
it is used as the benchmark pocket of Oseltamivir and
Zanamivir for preventing N-acetylneuraminic acid to be
released. However, it was reported that both Oseltamivir and
Zanamivir lead to drug resistance [11].
3. pocket_1nyj is the earliest known benchmark pocket. It is an
ion channel. When ions pass through this channel and enter
inside viral particles, they produce the pressure that allows the
transfer of viral genetic material and proteins PA, PB1 and PB2
into human cells. Additionally, pocket_1nyj is highly conserved
for all subtypes; hence it was used as the benchmark pocket to
design the first groups of drugs. For example, the drug
Amantadine was designed to block pocket_1nyj. Nevertheless,
its clinical efficacy is not very impressive.
4. pocket_3cm8 is a new benchmark pocket and it is also highly
conserved for all subtypes. However, its function is unclear
(despite the known function of 3cm8 [7,8]). We will not focus
on this pocket in our paper.
5. pocket_3hw3 is the largest pocket of the set. Although 3hw3 is
known as a cap-snitching domain and it is highly conserved,
pocket_3hw3 has not been mentioned in the literature before
now and its function is unclear. Despite our high degree of
confidence in AutoDock, we still find it challenging to design a
new drug that would be targeting it because we are familiar
with any molecular mechanism associated with pocket_3hw3.
4. Mining the computable features to measure drug efficacy
4.1. The minimal free energy (MFE). The minimal free
energy (MFE) is a well-known computable feature to describe
compatibility between a drug and a benchmark pocket. Let us
compare the values of MFE involving the nine drugs and five drug
binding pockets obtained though the process of blind docking
using AutoDock (see Table 2). In Table 2, the data underlined are
positive and others are negative. From Figure 1(A)–(E), we find
that the value of MFE is negative if the drug can be packed into
the pocket, while the value of MFE is positive if the drug cannot be
packed into the pocket. That is, the value of MFE is a good
computable feature to measure the benchmark pocket whether or
not it binds a drug.
However, the value of MFE alone is not sufficient to evaluate
the efficacy of a drug. In fact, if we only use the value of MFE as
evidence, we will get many conflict implications. For example, we
cannot distinguish the efficacies of Oseltamivir, Aspirin, and
Isosorbide because their values of MFE are same level (see the row
of pocket_2hu4 in Table 2), as well as, we cannot distinguish the
efficacies of Zanamivir, Amantadine, Oseltamivir, Aspirin,
Isosorbide and Herion because their values of MFE are almost
in the same level (see the row of pocket_3cm8). Moreover, we will
infer that Oseltamivir on pocket_1nyj is the best if we watch the
column of Oseltamivir in Table 2, and we will also infer that
Heroin on pocket_1nyj is best if we watch the row of pocket_1nyj
in Table 2 since the value of MFE for Heroin is significantly larger
than that value of MFE for Oseltamivir. Furthermore, we maybe
infer that Vancomycin is much better than Oseltamivir based on
the extreme values of MFE (27.30 and 23.07) in the row of
pocket_3hw3, which are significantly different because the std.
error is about 2.33 [11]. However, the ordinary knowledge tells us
that all 9 drugs are not effective on pocket_3hw3. Therefore, the
value of MFE is not sufficient to evaluate the efficacy of a drug. We
need more computable features to describe the efficacy of drugs.
Figure 1. The pockets filled with drug&drug complex. (A).The position of pocket_1rd8 filled with Aspirin and Isosorbide.(B). The position of
pocket_2hu4 filled with Aspirin, Isosorbide, Heroin, Oseltamivir and Azichromcin (C). The position of pocket_1nyj filled with Aspirin, Isosorbide,
Heroin, Amantadine, Zanamivir and Oseltamivir. (D). The position of pocket_3cm8 filled with Aspirin, Isosorbide, Heroin, Amantadine, Zanamivir and
Oseltamivir. (E). The position of pocket_3hw3 filled with all 9 drugs.
doi:10.1371/journal.pone.0033709.g001
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force. The binding force between a drug and a pocket, denoted
by F, is an essential feature. Roughly, F is proportional to the
number of non-covalent bonds if we ignore the angle. However,
the simplified estimate of F is not sufficient to determine the direct
fit between a drug and a pocket. Metaphorically, if we think of a
pocket as the doorframe and a drug as the door and if these non-
covalent bonds are distributed on one part of the doorframe, then
the stability of the fit between a drug and a pocket will not be very
good. Therefore, the distribution of all non-covalent bonds on
each doorframe is also very important. Only with this distribution
satisfying some threshold condition, we may find that increasing
the value of F will promote the stability of the fit between a drug
and a pocket.
We define the uniformity degree as:UD~N1=NwhereNis the
number of parts in the doorframe andN1is the number of parts in
the doorframe having non-covalent bonds. In practice, we require
the threshold to be 1/N which equivalent to the requirement
thatN1w1, and the value of UD=1 is the best.
Both the number and the uniformity degree of the non-covalent
bonds can be computed using Ligand Explorer. As an example of the
use of Ligand Explorer, we compute the number and distribution
of non-covalent bonds for Oseltamivir, Zanamivir and Amanta-
dine binding to pocket_2hu4 and pocket_1nyj, respectively.
In Table 3, A, B, C and D there are four domains that form the
pockets. We find that
1. The binding forces for Oseltamivir, Zanamivir and Amanta-
dine docked to pocket_2hu4 correspond to the energies of
95 kcal/mol, 75 kcal/mol and 75 kcal/mol, respectively. The
UDs of Oseltamivir, Zanamivir and Amantadine in pock-
et_2hu4 are 1, 0.5 and 0.5, respectively.
2. The binding forces using Oseltamivir, Zanamivir and Aman-
tadine to block pocket_1nyj corrspond to the energies
195 kcal/mol, 160 kcal/mol and 75 kcal/mol, respectively.
The uniform degrees of Oseltamivir, Zanamivir and Amanta-
dine on pocket_1nyj are 1.
The binding force F under the conditionN1w1plays a very
important role. Furthermore, F found for an arbitrary location
always indicates a conditional binding force, and we still use the
same symbol F, although this may create some confusion, so
attention should be paid to the context. Nevertheless, the
computation of F is not always carried out using the same rule.
It should based on the molecular mechanism of interaction
between a drug and a pocket. For example, if the pocket consists of
two domains and the role of the drug is to bind to these two
domains and prevent them from being separated from each other,
then the value of F is the smaller of the two forces calculated for
the two sides of the drug binding to the domains, respectively.
4.3. The airtight degree between a drug and a
pocket. According to the three features mentioned above,
pocket_1nyj appears better than pocket_2hu4 for drugs
Oseltamivir, Zanamivir and Amantadine. It is easy to
understand that pocket_1nyj is better than pocket_2hu4 for
Amantadine because pocket_1nyj is its benchmark pocket.
However, pocket_1nyj appears to be better than pocket_2hu4
for Oseltamivir and Zanamivir. This is hard to understand since
the benchmark pocket for Oseltamivir and Zanamivir is
pocket_2hu4. This implies that we need more features to
describe the drug’s efficacy.
From the diagrams of Oseltamivir, Zanamivir and Amantadine
binding to pocket_2hu4 (Figure 2(A)–(C)) and pocket_1nyj
(Figure 2(D)–(F)) we draw several pertinent observations. Based
on these six figures, we find a common point that three drugs do
not fill the two pockets as completely as possible. This may have
implications for the drugs’ limited efficacy. For example, the
mismatch between Amantadine, Oseltamivir or Zanamivir and
pocket_2hu4 is large enough that N-acetylneuraminic acid can be
released and therefore it suggests that Amantadine, Oseltamivir or
Zanamivir) is not effective in blocking pocket_2hu4. Similarly, the
mismatch between Amantadine and pocket_1nyj is also large
enough to pass ions through, and it also suggests that Amantadine
(even Oseltamivir or Zanamivir) is ineffective in blocking
pocket_1nyj if the ions produce large pressure. Therefore, it is
Table 2. The values of MFE between 9 drugs and 5 drug binding pockets.
benchmark Oseltamivir Zanamivir Amantadine Aspirin Azithromycin Isosorbide Vancomycin Heroin HEM
Pocket_1rd8 51.85 71.83 24.04 23.09 4560 23.6 19300 70.56 2360
Pocket_2hu4 23.97 27.43 23.95 23.64 27.67 23.85 4.95 25.36 26.56
Pocket_1nyj 26.66 27.14 26.97 25.16 4.52 25.71 5970 210.26 3.78
Pocket_3cm8 25.07 26.13 25.22 25.95 1380 25.70 10100 25.22 486.05
Pocket_3hw3 23.07 25.12 23.82 23.57 25.46 24.11 27.30 24.70 24.97
doi:10.1371/journal.pone.0033709.t002
Table 3. The amounts and the distribution of the non covalent bonds of Oseltamivir, Zanamivir and Amantadine on pocket_2hu4
and pocket_1nyj.
pocket pocket_2hu4 pocket_1nyj
Chain A B C D total A B C D total
Oseltamivir 4 4 9 2 19 8 2 18 11 39
Zanamivir 5 0 10 0 15 4 13 10 5 32
Amantadine 0 7 8 0 15 1 2 9 3 15
doi:10.1371/journal.pone.0033709.t003
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a pocket it fills. We call it the airtight degree.
It is clear the airtight degree depends on the substance
associated with the benchmark pocket. As mentioned above, the
substance in pocket_2hu4 is N-acetylneuraminic acid while the
substance in pocket_1nyj is a collection of ions but it was
misunderstood as viral cytoplasm. We define the airtight degree as
a 0–1 function: 1 if its substance cannot pass through it and 0
otherwise. This feature heavily depends on the knowledge of the
substance filling the pocket.
4.4. The inherent energy. Each channel must have an
inherent force and its result is that the drugs cannot bind strongly
enough to the protein surface. For example, the inherent energy of
pocket_2hu4 is this energy to release N-acetylneuraminic acid.
The inherent energy of pocket_1nyj is the exchange energy when
the ions flow into the virus to eject viral cytoplasm. We have not
been able to find relevant literature sources that discuss how to
compute these inherent energies. However, we know that the
inherent energy of pocket_2hu4 cannot be controlled by the
concentration of ions while the inherent energy of pocket_1nyj
can. This specificity will offset the weakness of Oseltamivir,
Zanamivir and Amantadine binding to pocket_1nyj. Generally,
the inherent energy of each channel has its specific mechanism
and value, and therefore there is no unique way to compute it. Just
this specificity offers an opportunity to design specifically effective
drugs. Let F0 be the inherent energy of a channel. The value of F0
will make the drug ineffective if we ignore it. Therefore, we
propose to introduce the inherent energy of pocket as a
computable feature.
In summary, we have assembled a set of five computable
features to describe the efficacy of a drug. It is clear that these five
features can be translated into four decisions: D1=max {0, -
MFE}, D2=max {0, F -F0}, D3=max {0, UD-0.5} and
D4=max {0, ATD}. Finally, we can show that a drug or a drug
& drug complex is effective if D1.0, D2.0, D3.0 and D4.0.
5 The universal algorithm to find drug & drug complexes
A universal program is used in this paper to search for an
optimal drug & drug complex, which is inspired by the model of
tight packing of balls into a box. We consider the pocket to
represent the box and drug molecules to represent the balls. For
clarity, we first describe the routine we use.
For a benchmark pocket, we first try to understand its molecular
mechanism especially the type of the associated substance and
then select the drugs from the DrugBank database to form the
panel of drugs under study. In this panel, the known drugs that
target this pocket should be included, the drugs which are as small
as the associated substance also should be contained in the panel
and drugs which are bigger than the known drugs aimed at this
pocket should also be assembled in the panel for comparison
proposed.
For a well-selected panel of drugs, we use the Autodock
procedure to check each drug whether or not it can be packed into
the given benchmark pocket. In practice, we do not add any prior
information to the Autodock procedure, but let Autodock blindly
dock a drug with a target protein using 5,000 iterations. We say
the drug can dock with the benchmark pocket, if the minimum
value of MFE within 5,000 iterations is negative and the position
corresponding to the minimum value is contained in the
benchmark pocket. We call it as the docked position.
The coordinates of a drug packed into a pocket are usually
different from the original coordinates provided by DrugBank. If
we regard the Autodock procedure as a mapping, then the drug
with the original coordinates is the original object and the drug
with the coordinates packed into a pocket is the image of the
object. If we ignore the overlap among these images, then the
envelope formed by the images of drugs is bigger than any single
image of a drug. We say that a drug is a cover of the benchmark
pocket if its image fills into the pocket fully enough so that the
associated substance of the pocket cannot pass through the pocket.
Generally, we say that a panel of drugs is a cover of the benchmark
pocket if the envelope formed by the images of the drugs may fill
the pocket fully enough so that the associated substance cannot
pass through the pocket. In particular, a drug & drug complex is
called a cover of the benchmark pocket, if the envelope formed by
the images of the drug of drug &drug complex fill the pocket fully
enough so that the associated substance cannot pass through the
pocket and these images do not overlap with each other. In
practice, some pockets may not have a cover even though the
panel is enlarged to contain the entire DrugBank. Moreover, some
Figure 2. The drugs docking with pocket_2hu4 and pocket_1nyj. (A). Oseltamivir docking with pocket_2hu4. (B). Zanamivir docking with
pocket_2hu4. (C). Amantadine docking with pocket_2hu4. (D). Oseltamivir docking with pocket_1nyj. (E). Zanamivir docking with pocket_1nyj. (F).
Amantadine docking with pocket_1nyj.
doi:10.1371/journal.pone.0033709.g002
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even though they may have a cover. For convenience, we use C to
denote the cover of the pocket induced by a panel of drugs.
If a benchmark pocket has an overlap cover C formed by N
images (i.e., the C is formed by N images and these images may
overlap), then we may further reduce it as the cover without
overlapping by removing the redundant images from the cover C
formed by the images of the panel. Using the combinations of
traditional Chinese herbs as a metaphor, we can define the king
drug and minister drugs in these combinations. We translate the
concepts developed by the traditional Chinese medicine into the
following typical circle searches:
Step 1. We select the largest image from the cover C as the
‘‘king’’ and denote it as K. We construct the subset c(K) of the
cover by deleting all of those images which overlap with K from
the cover.
If c(K) is empty, we output K alone and stop the search.
Otherwise, we choose the largest image from c(K) as the ‘‘first
minister’’ drug and denote it M1 and we construct c(K, M1) based
on c(K) by deleting these images which overlap with M1 from
c(K).
If c(K, M1) is empty, then we output K+M1 and stop the
search. Otherwise, we select the largest image from c(K, M1) as
the ‘‘second minister’’ and denote it by M2 and we continuously
construct the subset c(K, M1, M2) based on c(K, M1) by deleting
those images which overlap with M2 from c(K, M1).
If the c(K, M1, M2) is empty, then we output K+M1+M2 and
stop the search. Otherwise, we choose the largest drug from c(K,
M1, M2) as the ‘‘third minister’’ drug and denote it as M3 and
construct c(K, M1, M2, M3) based on c(K, M1, M2) by deleting
those images which overlap with M3 from c(K, M1, M2).
If c(K, M1, M2, M3) is empty, then output K+M1+M2+M3
and stop the search. Otherwise, we choose M4 from c(K, M1, M2,
M3) and continue to construct c(K, M1, M2, M3, M4).
Continuing this procedure, the search stops at most at 5 circles
because the sizes of the drugs in c(K) are less than half of the size of
K, and the sizes of drugs in c(K, M1) are less than a half of the M1,
the sizes of the drugs in c(K, M1, M2) are less than a half of M2,
etc. Therefore, within at most 5 circles, the sizes of the rest drug
will be less than the minimum size of all possible ligands.
Renewing the cover C with N images by moving the largest
image K from C, we obtain the renewed cover C1 with N-1
images. We use C1 to replace the original cover C and repeat the
above circle search. Inductively, we may renew the cover Ck based
on the cover Ck-1. This renewal program terminates when the size
of the largest image in Ck is less than the average size of the N
images because in this case the drug &drug complex absolutely
cannot cover the pocket.
Step 2. For all outputs corresponding to C, C1, C2,…,Cm,
where, m is the maximal integer such that Cm is still a cover of the
pocket, we check these m drug & drug complexes to determine
each of them whether or not can prevent that associated substance
pass through the pocket. This can be done either by visual
inspection or by computation. We only output those entire drug &
drug complexes which are the cover of the pocket.
The step 1 of the algorithm outputs only one drug & drug
complex for each renewal exercise of the cover. As the renewing is
finished, the number of outputs is at most N. Surely, the number
may be less than N/2 if the panel has N drugs with balancing
weights and we stop the renewing when the biggest drug in Ck is
less than the average weight of C. For each circle search in step 1,
the selection that is the largest in c(K), c(K, M1), c(K, M1, M2),
etc. Just this cause, the outputs of our algorithm may not contain
all covers without overlap. And therefore the final drug&drug
complex may not be the optimum complex in the sense of
computation. But it is suboptimal in some sense.
At the end, we analyze the total computational time for a given
target protein and panel of drugs. The first cost is taken for N
times to dock if the panel has N drugs. Autodock needs about
2 hours to confirm whether or not a drug can be packed into the
pocket in our PC (2.83 GHz/3 G memory). The second cost is
taken for search out the combinations of the king drug and minister
drugs. The time is taken to do that depends on both the N and the
weights of the drugs in the panel. But in practice the panel is not
too large and the distribution of the weights is fair, which will save
much time. For example, if we use our panel of 9 drugs, it only
took a few minutes to finish this search. The third cost is to check
the combinations whether or not satisfy D1.0, D2.0, D3.0,
and D4.0. It takes at most 50 minutes if the F0 is known.
Anyway, if the F0 is known, the time is no too long. However, in
order to estimate a bound of F0, it takes 4–5 days if we use the
molecular dynamic simulation to search the upper bound of F0.
Results
To show how to use the universal program, we use pocket_2hu4
and pocket_1nyj as examples because their molecular mechanisms
are well-known and the individually associated substance is also
known. Below we list the following findings:
For pocket_1nyj, there is no drug & drug complex to fit into it.
For pocket_2hu4, since Vancomycin can not be packed into
pocket_2hu4, then the cover is formed by 8 images of the rest
drugs. For convenience, we do not distinguish the drug and its
image. We arrange these 8 drugs orderly as Azithromycin, HEM,
Heroin, Zanamivir, Oseltaminvir, Isosorbide, Aspirin and Aman-
tadine according to the weights of the drugs shown in Table 1.
Running the step 1, we then may find all drug& drug complex
without overlap as below:
1. Azithromycin+Aspirin complex when Azithromycin is king.
2. HEM+Aspirin complex when HEM is the king.
3. Heroin+Amantadine complex when Heroin is the king.
4. There is no pair without overlapping when Zanamivir is king.
5. Oseltaminvir + Aspirin when Oseltaminvir is king.
6. We stop the circle searches for Isosorbide, Aspirin and
Amantadine because their sizes are less than the average of
all 8 drugs.
From this example, we may find that the algorithm to search the
combinations of the king and ministers largely reduces the
complexity. Comparably, if we enumerate all possible Drug&Drug
combinations formed by these 8 drugs which may be packed into
the pocket_2hu4, then the number of the possible 2-drug
combinations is 28, the number of the possible 3-drug combina-
tions is 56, the number of the possible 4-drug combinations is 70,
and etc. It will take too much time to exclude all unsatisfied
combinations. Among all possible 2-drug combinations, we may
find that Azithromycin+Aspirin, HEM + Aspirin, Heroin +
Amantadine, Oseltaminvir + Aspirin, Isosorbide + Aspirin, Aspirin
+Amantadine and Amantadine+Isosorbide are all 2-drug combi-
nations without overlap. This comparison shows that our
algorithm does not loss the essential results, although the last
three 2-drug combinations can not be output by the algorithm.
We continue to analyze what combinations are the covers of
pocket_2hu4 (step 2). Intuitively, Oseltaminvir+Aspirin cannot fill
pocket_2hu4 fully enough to prevent N-acetylneuraminic acid
(C11H19NO9) from being released. Therefore, Oseltaminvir+As-
pirin cannot cover pocket_2hu4. With the same reason, Zanamivir
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For the rest two 2-drug complexes HEM+Aspirin and Azithro-
mycin+Aspirin, HEM+Aspirin may fill pocket_2hu4 fully enough
so that N-acetylneuraminic acid cannot pass through here
(Figure 3(A)(B)). Moreover, the number of non covalent bonds
between HEM+Aspirin and pocket_2hu4 is 45. Therefore,
HEM+Aspirin should be a better drug&drug complex to be
recommended. However, HEM is an unapproved drug and we
can not use HEM & Aspirin to meet a clinical emergency
situation. Comparably, Azithromycin+Aspirin is also a cover of
pocket_2hu4, and the number of non covalent bonds between
Azithromycin+Aspirin and pocket_2hu4 is 34. Therefore, we
would like to recommend Azithromycin+Aspirin complex and we
focus on to evaluation of the efficacy of the Azithromycin &
Aspirin complex.
To show that the Azithromycin & Aspirin complex is predicted
to be effective we need only to show that D2.0 and D3.0
because D1.0 and D4.0 are obvious.
Using Ligand Explorer, we easily compute the UD and F of the
Azithromycin & Aspirin complex as follows: Azithromycin &
Aspirin complex has 34 non-covalent bonds binding to pock-
et_2hu4 and they are distributed on all parts of the pocket_2hu4.
Therefore, UD=1 and then D3.0, which is obvious. Important-
ly, the combined force F is about 170 kcal/mol.
To ensure D2.0, we need to estimate the inherent F0 in
pocket_2hu4. However, to measure F0 for pocket_2hu4 using
experimental methods is presently impossible. Alternatively, we
estimate the upper bound on F0 in pocket_2hu4 as 170 (kcal/mol).
In other words, we predict that the Azithromycin & Aspirin
complex is effective if F0 is less than 170 (kcal/mol).
The molecular dynamics simulation is regarded as the bridge
between theory and experiment and between microscopic and
macroscopic analyses. We may use the public software GRO-
MACS to computationally observe how much energy may pull
Azithromycin & Aspirin complex far from pocket_2hu4 in 2
angstrom. Typically, we let the moving speed of the spring be
0.001 nm/ps and the elasticity coefficients of the spring be
1,000,000 kJ mol
21 nm
22. Then we find that Azithromycin &
Aspirin complex can not be squeezed out the pocket during 50,000
iterations (equals to 0.1 ns). We further check the distance between
the geometrical center of Azithromycin & Aspirin complex and the
geometrical center of pocket_2hu4, it is ranging from 0 to 0.8
angstrom, and the maximal energy during this 0.1 ns. Therefore,
we may believe that distance is less than 0.5 angstrom is absolute
reliable threshold to say that drug cannot be squeezed out, while it
may be squeezed out if the distance is ranging to the interval from
0.5 to 1 angstrom. Next, we will use the minimal value of the
energies when distance ranges into [0.5, 1.0] (unit: angstrom) as
the critical value of energy so that drug cannot be squeezed out
binding pocket.
When the elasticity coefficient of the spring is increased to
10,000,000 kJ mol
21 nm
22, then we may find that Zanamivir,
Oseltamivir Azithromycin&Aspirin can be squeezed out pock-
et_2hu4 within 50,000 iterations. Then the critical energies of
Zanamivir, Oseltamivir Azithromycin & Aspirin are 409 kJ/mol,
551 kJ/mol and 682 kJ/mol, respectively. Especially, 682 kJ/mol
Figure 3. Two examples of drug & drug complexes. (A). The amplified picture shows that pocket_2hu4 was docked by Azichromycin & Aspirin
complex. (B). The amplified picture shows that pocket_2hu4 was docked by HEM & Aspirin complex. (C). The picture to show that 2D topological
diagram of Azichromycin & Aspirin complex.
doi:10.1371/journal.pone.0033709.g003
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estimated value through using the number of the non covalent
bonds. It makes us sure the method used to estimate the critical
energies is reliable. Further, we may infer that F0, min{409, 551}
if Zanamivir and Oseltamivir are assumed as the effective drugs. It
is certainly that Azithromycin &Aspirin docking with pocket_2hu4
satisfies D2.0i fF 0 ,409.
We have produced a movie to show that Azithromycin &
Aspirin complex cannot be separated from pocket_2hu4 using
GROMACS with fixed pull energy 682 kJ/mol (Supporting
Information S2). Note that the MD simulation only runs for
500,000 steps. It takes about 10 hours of CPU time to run it on
our computer and it corresponds to what we observe in the actual
situation of the Azithromycin & Aspirin complex docking with
pocket_2hu4 for a 0.1 ns time span. In other words, if we wanted
to observe the situation of the Azithromycin & Aspirin complex
docking with pocket_2hu4 for one minute, this would require
many years of computer simulations using a super computer.
To solve this very challenging computational problem, we
collect a sequence of distances from the geometrical center of the
pocket to the geometrical center of the drug over 50,000 steps. We
regard this sequence as the observed data of a stochastic process.
Using the signal processing approach, we can prove that
Azithromycin & Aspirin complex docks with pocket_2hu4 tightly
for ever. The detail proof is omitted. Anyway, simulation results
support that Azithromycin & Aspirin complex should be
considered to do the clinical experiments.
Discussion
In spite of the fact that state-of-the-art computational prediction
methods offer a high level of confidence, clinical validation
provides the final decision. It will be very reassuring if the efficacies
of these drug & drug complexes studied here are validated
clinically because the Azithromycin & Aspirin complex may be
readily used to treat all subtypes in group N1.
Fortunately, an easy and safe way can be used to provide
clinical validation. For example, using the dosage: 1 Azithromycin
dispersible tablet (0.1 g/tablet) and 2 aspirin enteric-coated tablet
(0.1 g/tablet), one of the authors, J Ruan experimented on
himself. After two hours following the drug administration
sneezing and sniffling stopped. The remaining symptoms disap-
peared after 12 hours following the second dosage. Of course,
large scale clinical tests are needed to confirm this anecdotal
observation.
For pocket_1nyj, there is no drug & drug complex to fit it.
However, Oseltamivir, Zanamivir or Amantadine may be
conditionally effective when they bind to pocket_1nyj. In fact,
we have also simulated the situation for Oseltamivir binding to
pocket_1nyj within 2 ns of simulation time. When the moving
speed of the spring is 0.001 nm/ps and the elasticity coefficient of
spring is 1,000 kJ mol
21 nm
22, Oseltamivir is separated from the
pocket_1nyj. In this case, F0 is about 58.4 kJ/mol. Therefore, if
the concentration of ions could be regulated down so that F0 is
much less than 58.4 kJ/mol, then D2.0. Therefore, it could then
become effective. We may find the following implications of this
conclusion.
It is possible to deduce why Oseltamivir is effective to treat
H1N1 in humans but not effective in avian species [20]. In fact,
Oseltamivir cannot inhibit the release of N-acetylneuraminic acid
and therefore it is useless to block pocket_2hu4. Comparably,
Oseltamivir can dock with pocket_1nyj even though it is not too
airtight to block the ions’ entry inside the bilayer, but it can
prevent the viral cytoplasm from flowing out of the lipid envelope
when the exchange energy F0 is not larger than the binding force
F of Oseltamivir. The specific characteristic of the inherent energy
F0 in pocket_1nyj can be controlled by changing the concentra-
tion of ions. Both humans and swine can drink large quantities of
water in a short period of time and therefore the concentration of
ions is reduced which results in reducing the value of F0 for
pocket_1nyj. With this insight, we can understand why Oseltami-
vir is not efficacious for avian species [20] since birds are unable to
drink much water in a short period of time.
The Azithromycin & Aspirin complex may be chemically bound
using covalent bonds to become a new drug. In this way, the
dosage of the new drug could be reduced which may avoid some
side effects due to the administration of Azithromycin or Aspirin
individually. For example, the Azithromycin & Aspirin complex
can be linked according to the distance matrix or the picture
shown in Figure 3(C). Of course, when it becomes a new drug it
will require more time and a high cost to determine its
pharmacokinetics, pharmacodynamics, side-effects and efficacy.
In summary, the five computable features proposed in this
paper are used to assess the efficacy of a drug or the referential
features to design novel drugs and drug combinations. Among
these five features, the airtight degree and the inherent force are
difficult to compute because they depend on the substance present
in the benchmark pocket. Unfortunately, we have no good
methods to estimate the inherent force at present which limits the
application of the drug & drug complex prediction methods until
we can accurately estimate the inherent forces. The four decisions
are the mathematical expressions of these five features. The key is
to check that D2.0. The condition D2.0 will lead to a more
predictable situation for the design of drugs.
In closing we briefly summarize the key insights arrived at in
this paper. Drug resistance is most often used to explain the lack of
efficacy of approved drugs and is usually linked to the presence of
mutations. However, in our view, this may be incomplete or
incorrect and could become a limiting factor in drug design. In
fact, the benchmark pockets of all approved drugs are found to be
highly conserved but the drug resistance still occurs. It is possible
that the real cause for the approved drugs to lose efficacy is
because some computable features have been ignored. There are
multiple causes of drug resistance and we need more computable
features to measure them. Urgently, we wish some readers may
develop an experimental method to measure the F0.
Supporting Information
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details of assemble the panel of drugs and explanation of drugs
docking in the same pocket.
(DOC)
Supporting Information S2 The movie to show that Azithro-
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when the elasticity coefficient of the spring is 1,000,000 kJ mol nm
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